A second oral GLP-1 just arrived, and this one is a true pill in mechanism. On April 1, the FDA approved orforglipron (Foundayo), the first oral, non-peptide GLP-1 for weight loss, taken any time of day with no food or water rules.
On April 1, 2026, the FDA approved orforglipron (Foundayo, Eli Lilly), the first oral, small-molecule, non-peptide GLP-1 receptor agonist for chronic weight management in adults with obesity, or overweight with a weight-related condition. Unlike earlier oral options, it can be taken any time of day without food or water restrictions; in trials it produced up to about 12.4 percent weight loss.
Just months after the first oral GLP-1 pill for weight loss, a second, mechanistically different oral option arrived.
Its approval on April 1 widened the oral GLP-1 landscape in a meaningful way.
The FDA approved orforglipron, branded Foundayo, as a once-daily oral GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, alongside diet and exercise. It is a small-molecule, non-peptide GLP-1, a key distinction from oral semaglutide, because its structure allows oral absorption without the strict empty-stomach timing earlier oral peptides require. It can be taken any time of day, with or without food and water. The approval, the first new molecular entity cleared under a national priority voucher program, was based on the ATTAIN Phase 3 program enrolling more than 4,500 participants.
In the ATTAIN-1 trial, average weight loss at 72 weeks reached about 7.8 percent at the lowest studied dose, 9.3 percent at a middle dose, and up to about 12.4 percent at the highest dose. Like other GLP-1 medicines, the label carries a boxed warning regarding thyroid C-cell tumors observed in rodents for the class, and the overall safety profile was described as consistent with the GLP-1 class.
For consumers, a flexible, any-time oral GLP-1 lowers practical barriers, no needles and no rigid dosing routine, which may help with adherence. It expands options for needle-averse patients and broadens what primary care can offer. But average trial results are not individual guarantees, side effects and suitability vary, and cost and access remain real factors. As with any prescription medicine, it is a clinical decision made with a licensed prescriber, not a self-directed choice.
Watch how access, pricing, and insurance coverage shape real-world uptake, and whether the convenience of an unrestricted oral pill improves adherence relative to injectables and earlier oral options. Orforglipron is also being studied for other conditions, including type 2 diabetes. For patients, the practical step is to discuss whether an oral GLP-1 fits their goals and health profile with a prescriber, and to verify any product is the FDA-approved version from a legitimate pharmacy.